Results of renal artery revascularization in the post-ASTRAL era with 4 years mean follow-up

Zachrisson, Karin; Krupić, Ferid; Svensson, Mikael; Wigelius, Ann; Jonsson, P. Andreas; Dimopoulou, Angeliki; Stenborg, Anna; Jensen, Gert; Herlitz, Hans; Gottsäter, Anders; Falkenberg, Mårten

doi:10.1080/08037051.2020.1756740

Cited by 2 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ability of BMT plus PTRA to reduce resistant hypertension was proven by three previous RCTs. 24,31,32 Our results also support recommendations of the American College of Cardiology and American Heart Association guidelines 33 and the Society for Cardiovascular Angiography and Interventions appropriate use criteria 34 that PTRA is beneficial in patients with resistant hypertension. Many researchers have suggested that patients showing renal blush grade, 36 an abnormal renal frame count, 35,36 unstable angina or congestive heart failure, 37,38 or flash pulmonary edema 38 have a significantly improved prognosis of hypertension.…”

Section: Discussionsupporting

confidence: 78%

“…One record was identified in a search of references. A total of 9 RCTs (EMMA, 23 SNRASCG, 24 DRASTIC, 25 STAR, 26 RASCAD, 27 CORAL, 28 RADAR, 29 NITER, 30 and ASTRAL 31 ) involving 2309 patients were chosen. Figure 1 shows a flowchart illustrating the search strategy for RCTs on PTRA and BMT in patients with ARAS.…”

Section: Resultsmentioning

confidence: 99%

“…There was a difference in sample size among the studies. Except for the total sample of the CORAL 28 and ASTRAL 31 studies, which exceeded 800, most of the other studies (EMMA, 23 SNRASCG, 24 RASCAD, 27 and RADAR 29 ) included less than 100 people. With regard to the mean degree of stenosis of the kidney, the RADAR study 29 exceeded 80% and DRASTIC exceeded 70%, while the others showed a similar degree of stenosis >50%.…”

Section: Resultsmentioning

confidence: 99%

“…Shetty et al. 46 identified five RCTs (EMMA, 23 SNRASCG, 24 DRASTIC, 25 STAR, 26 and ASTRAL 31 ) and discovered an upward trend in systolic blood pressure ( P =0.07), diastolic blood pressure ( P =0.12), or serum creatinine levels ( P =0.07) in patients who underwent PTRA compared with those who had BMT only.…”

Section: Discussionmentioning

confidence: 99%

“…Potential confounding factors between randomly assigned treatment groups might have reduced the chance of identifying advantages of PTRA over BMT. Second, some RCTs (EMMA, 23 SNRASCG, 24 DRASTIC, 25 STAR, 26 RASCAD, 27 CORAL, 28 and ASTRAL 31 ) included many patients with stenosis <70% who might not have obtained a benefit from PTRA. Third, the NITER study was terminated prematurely because of an insufficient inclusion.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Use of percutaneous transluminal renal angioplasty in atherosclerotic renal artery stenosis: a systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Objective For patients with atherosclerotic renal artery stenosis (ARAS), the role of percutaneous transluminal renal angioplasty (PTRA) remains inconclusive. This study aimed to comparatively evaluate the benefits of best medical therapy (BMT) plus PTRA and BMT alone in treating ARAS. Methods We performed a systematic review and meta-analysis, and searched for all randomized, controlled trials that reported patients with ARAS. The effectiveness and safety in the BMT plus PTRA and BMT alone groups were estimated, taking into account hypertension, stroke, renal events, cardiac events, and mortality. Results Nine randomized, controlled trials involving 2309 patients were included. In the BMT plus PTRA group, the incidence of refractory hypertension was significantly lower compared with that in the BMT alone group (odds ratio 0.09; 95% confidence interval 0.01, 0.70). However, there were no significant differences in the rates of stroke, renal events, cardiac events, cardiac mortality, and all-cause mortality between the two groups. Conclusions PTRA plus BMT improves blood pressure in patients with ARAS, but there is insufficient evidence for this therapy in improving stroke, renal events, cardiac events, and cardiac and all-cause mortality.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Use of percutaneous transluminal renal angioplasty in atherosclerotic renal artery stenosis: a systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

Atherosclerotic renal artery stenosis: how should we do?

Jiang

Zhang

2021

Chinese Medical Journal

View full text Add to dashboard Cite

Atherosclerotic renal artery stenosis (ARAS) is a common form of renal vascular disease and progressive disease. It could lead to resistant hypertension and renal insufficiency. It is almost associated with ischemic nephropathy with progressive decline in renal function and cardiac complications including flash pulmonary edema. The presence of ARAS is also associated with an increased risk of cardiovascular death. Common therapeutic strategies for ARAS include medical therapy and angioplasty with stenting.

show abstract

Results of renal artery revascularization in the post-ASTRAL era with 4 years mean follow-up

Cited by 2 publications

References 19 publications

Use of percutaneous transluminal renal angioplasty in atherosclerotic renal artery stenosis: a systematic review and meta-analysis

Use of percutaneous transluminal renal angioplasty in atherosclerotic renal artery stenosis: a systematic review and meta-analysis

Atherosclerotic renal artery stenosis: how should we do?

Contact Info

Product

Resources

About